

BLA 761210/S-008

CORRECTED SUPPLEMENT APPROVAL

Janssen Biotech, Inc.
Attention: Jasminder Kumar, PharmD, RPh
Associate Director, Global Regulatory Affairs
920 U.S. Route 202
Raritan, NJ 08869

Dear Dr. Kumar:

Please refer to your supplemental biologics license application (sBLA) dated and received March 3, 2025, and your amendments, submitted under section 351(a) of the Public Health Service Act for Rybrevant (amivantamab-vmjw) injection.

We also refer to our approval letter dated September 3, 2025, which contained the following error: In the *Highlights* of the U.S. Prescribing Information labeling, an incorrect date of 08/2025 appears in both the “Recent Major Changes” and “Revised:” date sections. It should be 09/2025 to reflect the approval date of this supplement.

The corrected action letter incorporates the correction of the error. The effective action date will remain September 3, 2025, the date of the original letter.

This Prior Approval sBLA provides for updates to the Dosage and Administration (2.5 Recommended Premedications) section of the Rybrevant U.S. Prescribing Information labeling, to include additional doses of dexamethasone prior to cycle 1 of amivantamab-vmjw to reduce the risk of infusion-related reactions.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at FDA.gov,¹ that is identical to the enclosed labeling (text for the Prescribing Information)

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

and include the labeling changes proposed in any pending “Changes Being Effectuated” (CBE) supplements.

Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending “Changes Being Effectuated” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in Microsoft Word format that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your supplement application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

If you have any questions, contact Monica Estrada, Regulatory Health Project Manager, at Monica.Estrada@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Paz Vellanki, MD, PhD
Supervisory Associate Director (Acting)
Division of Oncology 2
Office of Oncologic Diseases
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
 - Prescribing Information

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

PAZ J VELLANKI
09/16/2025 08:08:55 AM